Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...

A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...

A study is set to explore if artificial intelligence (AI) can help doctors make better decisions when it comes to treating prostate cancer. While prostate cancer diagnosis has become safer and more ...

The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artificial intelligence (AI)-powered risk-stratification tool for patients with ...

The NHS is embarking on a trial that could cut prostate cancer diagnosis times from weeks to a single day. The initiative uses artificial intelligence to analyze MRI scans, potentially transforming ...

FDA-authorized AI tools have the potential to help patients with prostate cancer get clearer answers instead of waiting weeks for genomic test results. FDA-authorized artificial intelligence (AI) ...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Associated Medical Professionals (A.M.P.) announced today the availability of the ArteraAI Prostate Test, an AI-powered risk stratification tool to help personalize ...

In cases of clinical equipoise, the highest MMAI score quartile could guide selective treatment intensification among patients with high-risk nonmetastatic prostate cancer. An artificial ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Digital Health News: Daniel Spratt, chair of radiation oncology at Case Comprehensive Cancer Center, commented on a new AI-enabled prostate cancer risk assessment tool has been developed to analyze ...